- Radformation is a leading provider of intelligent automation solutions for radiation oncology, focusing on enhancing the efficiency and accuracy of radiotherapy treatments.
- In May 2024, Radformation accelerated its AI capabilities by acquiring Limbus AI, and in February 2026, it secured USFDA 510(k) clearance for its ChartCheck Adaptive solution, which offers automated adaptive assessment workflows.
- Radformation has partnered with Icon Group to deploy its Offline Adaptive Assessment solution across 15 cancer centers in Australia, showcasing the practical application of its technology in clinical settings.
- Radformation's ideal buyers are healthcare providers and cancer treatment centers looking to improve treatment accuracy and workflow efficiency, making it a timely solution as the demand for advanced radiotherapy technologies grows.
Radformation's workforce is organized across 13 departments, with a notable concentration in Engineering, which employs 23 individuals, followed closely by Information Technology with 16 employees. Health Services also plays a significant role, contributing 14 members to the team. This distribution reflects a balanced functional mix, supporting the company's software development objectives while ensuring adequate coverage in operational and support functions.
The company operates across 37 locations, with a primary concentration in New York, NY, housing 14 employees. Other key locations include Atlanta, GA, with 3 employees, and Palo Alto, CA, with 2. The 'Other' category, comprising 65 employees, indicates a significant remote or distributed workforce, highlighting Radformation's flexible operational strategy and geographic diversity.
